In addition the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) trial demonstrated that lovastatin reduced cardiovascular events in patients with low LDL cholesterol and high CRP levels, while it conferred no clinical benefit in patients with both low LDL cholesterol and low CRP levels [2]. This evidence concerns the gene CRP and coronary atherosclerosis.